sigh relief sale ep despit abrupt drop march
detail guid offer recoveri back half
edward lifesci report posit one
result beat consensu sale estim forecast across everi busi
segment adj ep top consensu impress cent
procedur volum fell meaning last week march ew still report
y/i growth thv sale y/i ou thv revenu
previous model declin thv volum back half march
beat impli impact much milder japanes thv procedur volum
significantli hurt though ew expect neg impact beyond
good report manag offer thorough guidanc outlin pain
midpoint consensu follow gradual recoveri near-norm
level level quantit qualit detail includ guidanc
help reassur investor view ew commentari optimist
yet close match expect crucial procedur rel
short length stay like thv could among first recov mitral procedur
expect hit hard well guidanc reduc meaning
vs prior base new guidanc reduc
revenu meaning lower revenu well though model
midpoint revenu guidanc rang think -- base
earli report hospit prepar restart procedur pocket
 posit news flow germani -- ew land top half rang
robust gross margin expens control exhibit think new
ep estim near midpoint guidanc may conserv ew share
trade ntm ep estim well comp group reiter
segment surgic heart valv expect declin y/i
return y/i growth critic sale expect
rel flat neg impact lower surgic volum like
partial off-set increas demand monitor technolog use icu
patient
europcr catalyst ew anticip earli data evoqu tricuspid patient
day despit investor near-term focu pandem expect mitral
data serv catalyst addit see data pascal clasp
ce mark trial includ month data patient one-year
followup patient
valuat rate neutral continu feel ew current market
capit alreadi price lead market share fulli penetr matur
tavr market year signific mitral sale risk discuss
factset btig estim compani
document million except per share amount
edward rate neutral view edward well-round aortic mitral tricuspid portfolio make
competit long-term confid trans-sept mitral replac product could closer
previous estim howev feel market cap price mani thing go right bake success mitral program
updat disrupt
advanc mitral tricuspid portfolio
pandem resolv mid-summ gradual recoveri follow
maintain share tavr market
continu center adopt stabl price
rapid resolut pandem faster recoveri afterward
mitral program materi earlier expect
pandem last longer slower littl recoveri afterward
top-lin growth deceler competit eu intensifi
slowdown center adopt
delay mitral program
edward lead manufactur
transcathet surgic heart valv
product repair diseas aortic valv
addit compani also produc
hemodynam monitor system
hospit use lastli edward well-
round portfolio mitral tricuspid
therapi develop
repair replac
consolid revenu outperform forecast heel better expect revenu across
segment specif ww thv tmtt revenu came estim tavr growth
continu strong y/i slight deceler growth turn mitral report sale
quarter forecast sale achiev larg increas report
repres nearli tripl growth y/i sale even surgic heart valv segment slowli
cannib growth thv revenu brought beat project critic also beat project
come
adj gross margin sequenti model strong gross margin driven stronger
expect revenu across segment adj sg margin lower forecast due primarili decreas
compani meet travel expens administr cost result note compani plan
layoff time likewis spend lower expect result delay clinic trial
compani reiter long-term plan commit invest futur product develop project forward
modest decreas spend year result decreas expens adj ebit margin beat
estim handili higher tax rate anticip vs forecast slightli off-set revenu
beat bring adj ep higher model
overal reduc total revenu fall near midpoint guidanc rang given total revenu segment revenu
full year model lower-half rang particular reduc thv revenu full year
meaning model gradual revenu recoveri back half
 ew manag expens report strong margin reduc opex slightli reduc gross
margin slightli increas opex revenu overal ebit margin full year increas strength
tweak tax rate reduc share count base compani guid adj ep estim come
reflect lower revenu land near midpoint new guidanc rang
model revenu repres y/i declin non-gaap ep model recoveri
dip still lower estim project revenu come previou forecast
ep dip earlier estim
edward rate neutral feel ew current market capit alreadi price lead market share
fulli penetr matur tavr market year signific mitral sale btig provid price target
neutral-r stock risk includ disrupt competit patent litig slippag product timelin chang
procedur reimburs futur devic data fda possibl multipl contraction/expans
exhibit comp tabl larg cap med-tech compani
btig cover compani mention report
appendix analyst certif import disclosur
